Literature DB >> 11754500

Maspin expression in stage I and II oral tongue squamous cell carcinoma.

R Yasumatsu1, T Nakashima, N Hirakawa, Y Kumamoto, Y Kuratomi, K Tomita, S Komiyama.   

Abstract

BACKGROUND: A relatively high failure rate in the therapy of patients with early oral tongue squamous cell carcinomas (SCCs) is evidenced by untreated clinically negative neck lymph node metastasis. It is important to predict the malignant potential of oral tongue SCC in stage I and II patients, because the development of lymph node metastasis directly affects the prognosis of the patients.
METHODS: We evaluated maspin expression immunohistochemically in patients with stage I and II oral tongue SCCs and determined whether the expression level may be a useful factor in predicting metastatic potential and prognosis of these SCCs.
RESULTS: Clinical follow-up data showed a longer disease-free interval and overall survival periods for tumors immunohistochemically positive for maspin than for tumors negative for maspin, with the difference in disease-free interval being statistically significant (p =.01). The absence of maspin expression was found more frequently in cases of subsequent cervical lymph node metastasis than in cases without metastasis (p =.03).
CONCLUSIONS: Decreased maspin expression may be a significant factor associated with the metastatic potential of stage I and II oral tongue SCCs. Copyright 2001 John Wiley & Sons, Inc. Head Neck 23: 962-966, 2001.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11754500     DOI: 10.1002/hed.1139

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  13 in total

1.  Identification of differentially expressed genes in mouse hepatocarcinoma ascites cell line with low potential of lymphogenous metastasis.

Authors:  Xiao-Nan Cui; Jian-Wu Tang; Li Hou; Bo Song; Li-Ying Ban
Journal:  World J Gastroenterol       Date:  2006-11-14       Impact factor: 5.742

Review 2.  Proteomic research progress in lymphatic metastases of cancers.

Authors:  Junwei Zong; Chunmei Guo; Shuqing Liu; Ming-Zhong Sun; Jianwu Tang
Journal:  Clin Transl Oncol       Date:  2012-01       Impact factor: 3.405

3.  Value of ezrin, maspin and nm23-H1 protein expressions in predicting outcome of patients with head and neck squamous-cell carcinoma treated with radical radiotherapy.

Authors:  Paulette Mhawech-Fauceglia; Pavel Dulguerov; Amy Beck; Marta Bonet; Abdelkarim S Allal
Journal:  J Clin Pathol       Date:  2006-05-12       Impact factor: 3.411

4.  Differences in the expression of five senescence markers in oral cancer, oral leukoplakia and control samples in humans.

Authors:  Antonio Bascones-Martínez; Mercedes López-Durán; Jorge Cano-Sánchez; Lydia Sánchez-Verde; Ana Díez-Rodríguez; Pablo Aguirre-Echebarría; Emilio Alvarez-Fernández; Miguel Angel González-Moles; Jaime Bascones-Ilundain; Lorenzo Lo Muzio; Julián Campo-Trapero
Journal:  Oncol Lett       Date:  2012-03-19       Impact factor: 2.967

5.  Prognostic significance of the maspin tumor suppressor gene in pulmonary adenocarcinoma.

Authors:  Masanao Nakashima; Nobuyuki Ohike; Koichi Nagasaki; Mitsuru Adachi; Toshio Morohoshi
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-12       Impact factor: 4.553

6.  [Prognostic value of immunohistochemistry in salivary gland cancer].

Authors:  T Ettl; S Schwarz; T Kühnel; P Stockmann; T E Reichert; O Driemel
Journal:  HNO       Date:  2008-02       Impact factor: 1.284

7.  Maspin and MCM2 immunoprofiling in salivary gland carcinomas.

Authors:  Shaimaa E Ghazy; Iman M Helmy; Houry M Baghdadi
Journal:  Diagn Pathol       Date:  2011-09-26       Impact factor: 2.644

8.  The associated expression of Maspin and Bax proteins as a potential prognostic factor in intrahepatic cholangiocarcinoma.

Authors:  Antonello A Romani; Paolo Soliani; Silvia Desenzani; Angelo F Borghetti; Pellegrino Crafa
Journal:  BMC Cancer       Date:  2006-10-26       Impact factor: 4.430

9.  Role of maspin in cancer.

Authors:  Rossana Berardi; Francesca Morgese; Azzurra Onofri; Paola Mazzanti; Mirco Pistelli; Zelmira Ballatore; Agnese Savini; Mariagrazia De Lisa; Miriam Caramanti; Silvia Rinaldi; Silvia Pagliaretta; Matteo Santoni; Chiara Pierantoni; Stefano Cascinu
Journal:  Clin Transl Med       Date:  2013-03-07

10.  Maspin is a tumour suppressor that inhibits breast cancer tumour metastasis in vivo.

Authors:  Charles H Streuli
Journal:  Breast Cancer Res       Date:  2002-05-16       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.